Jaguar Health, Inc. (JAGX): Operating Cash Flow
-$23.69M
Year ended 2025-12-31
-$6.68M
Trailing 12 months to 2026-06-30
| Period ended | Operating Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$23.69M | n/m | 2026-04-07, From 2025-01-01 |
| 2024-12-31 | -$29.38M | n/m | 2026-04-07, From 2024-01-01 |
| 2023-12-31 | -$33.24M | n/m | 2025-03-31, From 2023-01-01 |
| 2022-12-31 | -$33.10M | n/m | 2024-04-01, From 2022-01-01 |
| 2021-12-31 | -$34.97M | n/m | 2023-03-24, From 2021-01-01 |
| 2020-12-31 | -$15.28M | n/m | 2022-03-11, From 2020-01-01 |
| 2019-12-31 | -$20.46M | n/m | 2021-03-31, From 2019-01-01 |
| 2018-12-31 | -$22.73M | n/m | 2020-04-03, From 2018-01-01 |
| 2017-12-31 | -$9.82M | n/m | 2019-04-10, From 2017-01-01 |
| 2016-12-31 | -$14.41M | n/m | 2018-04-09, From 2016-01-01 |
| 2015-12-31 | -$14.32M | n/m | 2017-02-15, From 2015-01-01 |
| 2014-12-31 | -$5.36M | n/a | 2016-03-29, From 2014-01-01 |
Operating Cash Flow at similar companies
| Company | Year ended | Operating Cash Flow | Change YoY |
|---|---|---|---|
| Jaguar Health, Inc. (JAGX) | 2025-12-31 | -$23.69M | n/m |
| Prelude Therapeutics Inc (PRLD) | 2025-12-31 | -$56.30M | n/m |
| Crescent Biopharma, Inc. (CBIO) | 2025-12-31 | -$71.53M | n/m |
| Emmaus Life Sciences, Inc. (EMMA) | 2025-12-31 | -$11.0K | n/m |
| Evommune, Inc. (EVMN) | 2025-12-31 | -$76.44M | n/m |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | 2025-12-31 | -$99.84M | n/m |
| Janux Therapeutics, Inc. (JANX) | 2025-12-31 | -$82.23M | n/m |
| Zenas BioPharma, Inc. (ZBIO) | 2025-12-31 | -$172.33M | n/m |
| Precigen, Inc. (PGEN) | 2025-12-31 | -$87.83M | n/m |
Compare JAGX, PRLD, CBIO, EMMA side by side · Screen every company in Pharmaceutical Preparations ↗